8-K: Vivos Therapeutics Secures $4 Million Through Warrant Exercise, Issues New Warrants

Vivos Therapeutics has successfully raised approximately $4 million through the exercise of existing warrants and issued new warrants as part of an inducement agreement.

Summary

• Vivos Therapeutics entered into a warrant inducement agreement with a holder to exercise existing Series B warrants for $4.02 per share, resulting in approximately $4 million in gross proceeds.
• In exchange for the immediate exercise, Vivos issued new Series B-1 and B-2 warrants to the holder, totaling 1,470,592 shares at an exercise price of $5.05 per share.
• The Series B-1 warrants have a 5-year term, while the Series B-2 warrants have an 18-month term.
• The company has agreed to register the shares underlying the new warrants for resale by April 5, 2024, and to use commercially reasonable efforts to have the registration effective within 60 days of filing.
• Vivos is restricted from issuing further common stock or equivalents for 45 days after the closing of the inducement transaction, and from variable rate transactions for six months after the resale registration is effective.
• A.G.P./Alliance Global Partners acted as the exclusive financial advisor for the transaction, receiving a 7% cash fee and up to $30,000 for legal expenses.

Sentiment

Score: 7

Explanation: The document indicates a successful capital raise, which is positive. However, the restrictions on future issuances and the fees paid to the financial advisor are potential negatives. Overall, the sentiment is moderately positive.

Positives

• The company successfully raised $4 million in gross proceeds.
• The inducement agreement provides the company with additional capital.
• The resale of the shares underlying the exercised warrants has already been registered.
• The new warrants have a higher exercise price than the previous warrants, potentially increasing future capital if exercised.
• The company has secured a financial advisor for the transaction.

Negatives

• The company is restricted from issuing further common stock or equivalents for 45 days after the closing of the inducement transaction.
• The company is restricted from variable rate transactions for six months after the resale registration is effective.
• The company is obligated to pay a 7% cash fee to the financial advisor, plus up to $30,000 in legal expenses.

Risks

• The company may face challenges in meeting the deadlines for filing and effectiveness of the resale registration statement.
• The restrictions on issuing further common stock or equivalents could limit the company's financial flexibility in the short term.
• The company may be subject to liquidated damages if the new warrant shares are not delivered on time upon exercise.
• The new warrants contain beneficial ownership limitations that could affect the holder's ability to exercise them fully.

Future Outlook

The company intends to use the net proceeds from the inducement transaction for general working capital and corporate purposes. The company is also focused on registering the new warrant shares for resale.

Industry Context

This type of transaction is common for small-cap companies seeking to raise capital. The use of warrants and inducement agreements is a way to incentivize investors to provide immediate funding.

Comparison to Industry Standards

• The use of warrants with cashless exercise provisions is a common practice in small-cap financings, similar to companies like Cassava Sciences and Ocugen.
• The 7% cash fee for the financial advisor is within the typical range for such transactions, comparable to fees seen in similar deals for companies like Agenus and Cellectar Biosciences.
• The restrictions on future equity issuances are also standard to protect the investor, similar to lock-up agreements in other private placements.
• The Black-Scholes valuation method for the warrants in the event of a fundamental transaction is a common industry practice, used by many companies in similar situations.

Stakeholder Impact

• Shareholders may experience dilution if the new warrants are exercised.
• The company's financial position is strengthened by the $4 million capital raise.
• The company's ability to raise further capital in the short term is limited by the restrictions on equity issuances.

Next Steps

• The company will file a resale registration statement for the new warrant shares by April 5, 2024.
• The company will work to have the resale registration statement declared effective within 60 days of filing.
• The company will use the net proceeds for general working capital and corporate purposes.

Key Dates

Keywords

warrant inducement, common stock, private placement, capital raise, warrants, exercise price, registration statement, securities, AGP, Vivos Therapeutics